about
Pharmacogenetics of antidepressants and antipsychotics: the contribution of allelic variations to the phenotype of drug responseNew atypical antipsychotics for schizophrenia: iloperidoneSummary of information on human CYP enzymes: human P450 metabolism data.Genome-wide pharmacogenomic analysis of response to treatment with antipsychotics.An assessment of iloperidone for the treatment of schizophrenia.Relationship between P-glycoprotein and second-generation antipsychotics.Plasma amisulpride in relation to prescribed dose, clozapine augmentation, and other factors: data from a therapeutic drug monitoring service, 2002-2010.Cytochrome P450 polymorphisms and response to antipsychotic therapy.Interactions between the cytochrome P450 system and the second-generation antipsychotics.Critical appraisal of lurasidone in the management of schizophrenia.Olanzapine: a 5-year perspective.Iloperidone: a new benzisoxazole atypical antipsychotic drug. Is it novel enough to impact the crowded atypical antipsychotic market?The pharmacologic management of insomnia in patients with HIV.Genetic polymorphism in cytochrome P450 2D6 (CYP2D6): Population distribution of CYP2D6 activity.Efficacy, safety and tolerability of Symbyax for acute-phase management of treatment-resistant depression.Safety evaluation of zotepine for the treatment of schizophrenia.Antipsychotic drug toxicology in children.Pharmacokinetics and metabolism update for some recent antipsychotics.Safety and pharmacokinetics of atypical antipsychotics in children and adolescents.Safety of antipsychotic drugs: focus on therapeutic and adverse effects.Update on the management of symptoms in schizophrenia: focus on amisulpride.Distribution of the methylpiperazinopyridobenzoxazepine derivative JL13, a potential antipsychotic, in rat brain.[Pharmacological treatment of psychosis in epilepsy].Amisulpride doses and plasma levels in different age groups of patients with schizophrenia or schizoaffective disorder.
P2860
Q28252209-8F4CE453-9BC9-4C9B-A500-52567B76740AQ30482195-B8A32564-4801-43BF-8E32-8FCD6CF1F8A0Q32103802-33A08963-BBDC-4B3E-92BD-5454D0868D74Q33926334-11737A1A-2A75-4FB7-86B1-6357E991C3CCQ34091005-F130E114-1397-4BB4-AF24-B4CCB716F116Q34208133-C8C81F45-AD82-4CFE-A357-9B3F689F85BFQ34418688-1A8E1686-E4D2-47F2-AB32-8C2ED6A09E75Q34612118-93CBA52F-B2AE-448E-B6FA-67621B1BF21EQ35096587-C9EC156D-A059-4C34-86DC-65259A2CF64DQ35939685-37C72B0E-241A-4EC1-B212-C6A186D15843Q36511290-2F437DBA-5F96-4C47-83BC-8BFAD0E1FCE4Q37038991-339EDBC9-E12F-4791-8FA8-F58EDCEA2EF1Q37234441-61D54E4D-7E13-4103-966C-BC78D0872A04Q37698407-CC028E7F-A35F-4730-8D17-619625EE3918Q37737291-E69A3305-0F07-476F-BE5B-727811E9BDDBQ37757004-34703E27-AD0B-4094-A188-1F7BCC2B8993Q37852719-F53691C9-2E60-4B48-B585-4DBB3F677298Q37863118-433B1032-2616-4857-94D4-69ADC396C90CQ38099224-70BA0FD0-241B-463B-826A-7D2F4DCA4D15Q38224339-1959EA97-90EB-4049-A3C3-A5538FF1F4B6Q41529086-DCE2E053-D593-4D50-A88A-C23FC0C1EC20Q43567554-7BA3DE76-18BB-4D87-8401-F3C94A1E8FD1Q44825253-BF2F3620-1748-4776-828D-1865F8D9B5CFQ46533503-5C6D2290-CF90-4C09-95B2-F279AFA6FCE9
P2860
description
2000 nî lūn-bûn
@nan
2000 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
name
Biotransformation of Post-Clozapine Antipsychotics
@ast
Biotransformation of Post-Clozapine Antipsychotics
@en
type
label
Biotransformation of Post-Clozapine Antipsychotics
@ast
Biotransformation of Post-Clozapine Antipsychotics
@en
prefLabel
Biotransformation of Post-Clozapine Antipsychotics
@ast
Biotransformation of Post-Clozapine Antipsychotics
@en
P1476
Biotransformation of Post-Clozapine Antipsychotics
@en
P2093
Silvio Caccia
P304
P356
10.2165/00003088-200038050-00002
P577
2000-05-01T00:00:00Z
P6179
1027203854